BioTools Innovator

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

BacStitch DNA is a DNA assembly revolution that accelerates protein, pathway, and cellular engineering.

BioRaptor is developing an operating system tailored for biotech and biopharma firms, focusing on empowering scientists through the use of artificial intelligence. The platform integrates and harmonizes data from various sources, enabling scientists to leverage this information to design more effective experiments and gain insights that enhance their understanding of experimental outcomes. By facilitating data-driven decision-making, BioRaptor aims to improve productivity and provide valuable insights that can accelerate the research and development processes within the biotech sector.

Atomnaut is a developer of advanced microscopy technology, specifically a 3D atomic resolution microscope that utilizes unique projection technology to accurately identify and detect the position of atoms in three-dimensional space. This innovative tool enables detailed imaging, analysis, sequencing, and design at the atomic level, allowing scientists to understand and manipulate materials more effectively. The company specializes in materials engineering and offers a range of advanced materials, including silicon transistors, high-strength steels, nanowires, quantum dots, tungsten alloys suitable for fusion or aerospace applications, and nanostructured light and strong aluminum alloys. Atomnaut's technology supports a variety of scientific and engineering applications, pushing the boundaries of materials research and development.

TeraCyte Analytics predicts human medication response by collecting since-cell dynamics, resulting in extraordinary prediction value.

Argome is a smart nanoparticle platform that allows for a uniform next-generation multiomic approach.

Scribe Biosciences specializes in single-cell analysis tools that enhance clinical and research applications. The company employs its proprietary technology, Printed Droplet Microfluidics (PDM), which allows for flexible and reconfigurable fluid handling at the picoliter scale. By utilizing fluorescence-activated microfluidic droplet sorting along with a specialized substrate, Scribe Biosciences can manipulate single cells and fluid aliquots with high throughput. This innovative approach aids researchers and healthcare professionals in gaining insights into various processes, particularly those related to infectious diseases and cancer.

BennuBio, Inc. is a technology company specializing in the development of flow cytometry equipment designed for the sorting and analysis of cells and particles in various applications, particularly those requiring the recovery of rare cells. The company offers The Velocyt system, which enables the detection of rare events such as activated T cells, circulating tumor cells, and fetal cells in maternal blood, supporting advancements in personalized medicine and drug discovery. Additionally, BennuBio provides spheroid generation systems and high-volume sorting systems, along with technical and application support services. Founded in 2018 and based in Albuquerque, New Mexico, BennuBio focuses on delivering innovative cell analysis solutions that accommodate a wide range of sample sizes and particle dimensions.

Switchback Systems is an early-stage startup founded in 2019 by Mary Noe, specializing in the development of a scalable DNA synthesis platform. The company aims to significantly reduce the time, cost, and waste associated with nucleic acid applications. Its innovative platform utilizes advanced technologies to facilitate the use of cell structure as a data storage medium. By offering a benchtop DNA printer, Switchback Systems provides the healthcare industry with on-demand biological discovery capabilities, catering to the needs of laboratories and enhancing their research efficiency.

Aureka Biotechnologies is an innovative biotech company focused on transforming the pharmaceutical industry to improve healthcare accessibility. The firm has developed a therapeutic discovery platform that utilizes advanced machine learning and artificial intelligence technologies to streamline the therapeutic design process. By digitalizing drug development at scale, Aureka aims to identify and design potential drug candidates more efficiently, ultimately leading to the creation of novel treatments. This approach seeks to significantly lower costs and reduce the time required for bringing new therapies to market, thereby enhancing the overall effectiveness of the pharmaceutical sector in addressing various health challenges.

CRISPR Analytics Platform expands the data and analytics available for CRISPR gene editing, enabling its partners to produce products more quickly. The platform is based on the CRISPR-Chip, a device that is uniquely able to measure CRISPR activity directly.

ReelReactor specializes in the development of continuous reactor technologies aimed at enhancing the throughput, efficiency, and quality of chemical, pharmaceutical, and biological products and therapies. This innovative technology has the potential to transform manufacturing processes across various industries by reducing costs and improving the consistency and quality of products. As a result, ReelReactor's solutions may facilitate greater accessibility to vital therapies, ultimately benefiting a wide range of sectors reliant on high-quality manufacturing.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

Aopia Biosciences is a biotechnology company dedicated to advancing bioengineering solutions for biomedical research, diagnostics, and therapeutic applications. The company specializes in ultra-high sensitivity biomarker detection, which is crucial for early disease diagnosis and monitoring treatment efficacy. Aopia's platform supports research focused on extracellular vesicles (EVs) and exosomes, providing innovative tools that enhance the understanding of disease mechanisms and improve patient outcomes. Through its cutting-edge technologies, Aopia aims to facilitate significant advancements in the fields of diagnostics and therapeutics.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

PAK BioSolutions specializes in the manufacture of biopharmaceuticals, focusing on automation equipment and single-use flow kits designed for continuous production processes. The company offers a range of comprehensive solutions that include automated systems and consumables suitable for both laboratory and GMP facilities. By implementing these continuous processes, PAK BioSolutions aims to enhance productivity for its clients while reducing capital costs and minimizing space requirements. Additionally, the company provides consulting services to further support its clients in optimizing their manufacturing operations.

Andson Biotech specializes in developing innovative Process Analytical Technologies (PAT) tailored for advanced biomanufacturing, particularly in cell-based bioprocesses. The company has created a proprietary secretome analysis system that streamlines and enhances traditional analytical measurements typically conducted through mass spectrometry workflows. By leveraging its core technologies, Andson Biotech aims to accelerate and simplify the drug discovery process, enabling the efficient development of assays. This commitment helps bring advanced therapies, including recombinant proteins, monoclonal antibodies, and vaccines, to market more rapidly, ultimately benefiting healthcare professionals and patients alike.

Clara Biotech is a platform technology that allow for the isolation of specific cellular markers (exosomes) from very small fluid samples enabling liquid biopsy for the very early detection of cancer, Alzheimer's Disease and many others. These same markers can also be turned into a precision medicine drug delivery platform delivering targeted drugs directly to the cells being targeted. The current gold standard is a 12 hours ultra-centrifugation process. Ours is the only platform that can take any biofluid source, and extract any species of pure viable exosome into pure solution. We are the bridge that moves research to patient. Exosomes are one of the next major breakthroughs in Biotech. We are Clara. We are exosomes.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Atom Bioworks focuses on developing a pattern-recognition enabled platform that combines DNA, antibody mimics, and advanced computational techniques for the detection and treatment of infectious diseases and cancer. The platform utilizes computational biology, quantum chemistry, software, and machine learning to identify specific surface protein patterns associated with diseases. By creating corresponding pattern-matching constructs, Atom Bioworks aims to enhance researchers' capabilities in early diagnosis and therapeutic interventions, ultimately improving medical applications in the fight against infectious diseases and cancer.

Ananda Devices is a biotech company specializing in advanced nano-organization technology aimed at enhancing research and development in the pharmaceutical, food, and cosmetic industries. This proprietary technology facilitates the innervation of various tissue types and allows for the miniaturization of existing biological models. By creating co-culture models that provide access to individual components, Ananda Devices enables researchers and physicians to generate detailed and physiologically relevant data tailored to their specific requirements.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Opera Bioscience provides researchers high quality and cheap reagents and material proteins.

Ferrologix was launched as a startup from the University of California Los Angeles emerging from professor Dino Di Carlo's lab in the department of bioengineering. It has a unique magnetic-based instrument and disposable cartridge that can transport, filter, and organize single cells for precision analysis or therapeutic manufacture. Pioneering a technique called Digital Magnetic Sorting, Ferrologix is developing a suite of tools to assist, accelerate, and scale the development of precision medicine research, next-gen diagnostics, and cellular therapies. ​

Zymvol accelerates the discovery & development of new industrial enzymes through computer simulations.

GenNext Technologies is a platform that provides instrumentation, software, and services to structural biology researchers within the biopharmaceutical industry.

Cellbox Solutions is a young technology company that focuses on innovative logistic solutions for the global BioMed industry.

CellChorus specializes in advanced single-cell analysis for biopharmaceutical companies, utilizing its proprietary TIMING™ platform. This visual artificial intelligence technology enables dynamic evaluation of cell activation, killing, and movement over time. By integrating data on kinetics and interactions with insights from single-cell RNA sequencing and flow cytometry, CellChorus provides healthcare organizations with a comprehensive understanding of cellular function, state, and phenotype. This innovative approach aims to enhance the development and efficacy of immuno-oncology therapies and other medical treatments.

DropGenie is building connected hardware to automate gene editing. They are accelerating the pace of discovery through the generation of standardized and compatible scientific information.

Dalton Bioanalytics is a developer of analytical technology that unlocks access to the wealth of information available in the blood. It resolves the inefficiency and expense that plagues traditional laboratory testing by digitizing the biochemical composition of blood and translating that digital signature into a comprehensive array of actionable health insights. The analytical technology deciphers the biochemical signature of blood to build narratives about internal biology. Dalton was headquartered in Los Angeles, California in 2019.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction.

xMD Diagnostics, based in Annapolis, Maryland, specializes in biotechnology within the healthcare sector. The company develops molecular diagnostics tools that use high-throughput microdissection technology to improve cancer diagnosis and management. These tools are designed to isolate, procure, and enrich cells of interest from biopsy and other specimen samples. This process facilitates various downstream analyses, including PCR, genomic or proteomic testing, and next-generation sequencing. By enhancing the capabilities of clinical and research laboratories, xMD Diagnostics supports pathologists, oncologists, and other healthcare professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Elemental Machines, Inc., founded in 2014 and based in Cambridge, Massachusetts, operates within the technology sector, focusing on revolutionizing science-based industries through its smart lab platform. This platform leverages artificial intelligence to provide data-driven insights that enhance laboratory operations, research, development, and manufacturing processes. By continuously monitoring equipment and environmental variables using intelligent sensors, it offers improved clarity, transparency, consistency, and repeatability. The system also sends alerts via text and email for any anomalous results, facilitating clients in refining and accelerating their work across all stages of product innovation. Through the collection of new data sets, Elemental Machines enables advanced analytics that supports experimental reproducibility and optimizes operational efficiency.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Enrich Biosystems focuses on developing innovative technologies for cell imaging, analysis, and capture, aimed at advancing cell-based therapies and precision medicine. The company has created a unique single-cell isolation platform that operates without microfluidics, utilizing dissolvable microwells and visual enrichment techniques. This approach addresses significant challenges faced by existing technologies, offering a streamlined workflow for cell culturing and kinetics profiling. Enrich Biosystems' solutions enhance biomedical research by allowing healthcare professionals to efficiently capture and analyze individual cells based on their functions, thereby facilitating progress in various critical life science applications.